Abstract: The present invention relates to compounds of Formula I, II or III, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: The present invention relates to compounds of Formula I, II or Ill, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: Disclosed herein are compound useful for inhibition of hormone sensitive lipase, pharmaceutical compositions of these compounds, and methods of treatment using these compounds.

Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: Novel macrolide compounds of the formula ##STR1## and pharmaceutically acceptable salts, esters, amides and prodrugs thereof, wherein X is a substituent selected from among radicals having the subformulae ##STR2## and other heterocyclic radicals, as well as pharmaceutical compositions and methods of immunomodulatory treatment utilizing the same.

Abstract: Immunomodulatory macrocyclic compounds having the formula ##STR1## and the pharmaceutically acceptable salts, esters, amides and prodrugs thereof, wherein Y is selected from one of the formulae ##STR2## as well as pharmaceutical compositions containing the same and methods of their use.

Abstract: Immunomodulatory macrocyclic compounds having the formula: ##STR1## and pharmaceutically acceptable salts, esters, amides and prodrugs thereof, as well as pharmaceutical compositions containing such compounds and therapeutic methods of their use.

Abstract: Novel macrolide compounds of the formula ##STR1## and pharmaceutically acceptable salts, esters, amides and prodrugs thereof, wherein X is a substituent selected from among radicals having the subformulae ##STR2## and other heterocyclic radicals, as well as pharmaceutical compositions and methods of immunomodulatory treatment utilizing the same.

Abstract: Immunomodulatory macrocyclic compounds having the formula: ##STR1## and pharmaceutically-acceptable salts, esters, amides and prodrugs thereof, as well as pharmaceutical compositions containing the same, which possess immunosuppressive, antimicrobial, antifungal, antiviral, antiinflammatory and antiproliferative activity, as well as the ability to reverse chemotherapeutic drug resistance.

Abstract: Immunomodulatory macrocyclic compounds having the formula ##STR1## and pharmaceutically acceptable salts, esters, amides and prodrugs thereof, wherein X is a group having the formula ##STR2## as well as pharmaceutical compositions containing the same.

Abstract: Immunomodulatory macrocyclic compounds having the formula: ##STR1## and pharmaceutically acceptable salts, esters, amides and prodrugs thereof,where R.sup.8 and R.sup.9 are selected such that one of R.sup.8 and R.sup.9 is hydrogen and the other is --S(O).sub.s --heterocyclic,as well as pharmaceutical compositions containing such compounds and therapeutic methods of their use.

Abstract: Immunomodulatory macrocyclic compounds having the formula ##STR1## and pharmaceutically acceptable salts, esters, amides and prodrugs thereof, wherein one of R.sup.107, R.sup.108, R.sup.109 and R.sup.110 is a radical having the formula ##STR2## as well as pharmaceutically compositions containing such compounds and methods of immunomodulatory therapy utilizing the same.

Abstract: Immunomodulatory macrocyclic compounds having the formula: ##STR1## and the pharmaceutically acceptable salts, esters, amides and prodrugs thereof, wherein R.sup.8 and R.sup.9 are selected such that one of R.sup.8 and R.sup.9 is hydrogen, and the other is chosen from the group consisting of:(1) --OC(.dbd.NR.sup.10)-NHR.sup.10 ;(2) --OC(.dbd.O)-R.sup.11 ; and(3) --OC(.dbd.O)-NR.sup.12 R.sup.13 ;(4) --OC(.dbd.O)-N(OR.sup.14)R.sup.12 ;(5) --OC(.dbd.O)-NHNR.sup.12 R.sup.13 ;(6) --OC(.dbd.O)-NH-NHC(.dbd.O)-NR.sup.12 R.sup.13 ;(7) --OC(.dbd.O)-NH-NHS(O).sub.2 --NR.sup.12 R.sup.13 ; and(8) --OC(.dbd.O)-NH-NHC(.dbd.NR.sup.21 )-NR.sup.12 R.sup.13. as well as pharmaceutical compositions containing such compounds and methods for their use in immunosuppressive, antimicrobial, antifungal, antiviral, antiinflammatory and antiproliferative therapy.

Abstract: Novel macrolide compounds of the formula ##STR1## and pharmaceutically acceptable salts, esters, amides and prodrugs thereof, processes for the preparation of the compounds of the invention, intermediates useful in these processes, a pharmaceutical composition, and a method of treating immunomodulatory disorders are disclosed.

Abstract: Activated macrolactam compounds having the formula ##STR1## wherein n is zero or one, R.sup.101 is selected from the group consisting of methyl, ethyl, allyl, propyl and cyclopropylmethyl;R.sup.102 is hydrogen, and R.sup.103 is selected from the group consisting of hydrogen, hydroxy and a protected hydroxy group or, taken together, R.sup.102 and R.sup.103 form a bond;R.sup.104 and R.sup.105 are chosen such that one is hydrogen while the other is -OS(O).sub.2 F; andR.sup.106 is selected from the group consisting of hydrogen, a protected hydroxy group, loweralkyl, alkenyl, cycloalkyl, aryl and arylalkyl,as well as processes for making such compounds and methods for their use in the preparation of C-32-modified derivatives of ascomycin or the congeners or analogs thereof.

Abstract: Immunomodulatory macrocyclic compounds having the formula ##STR1## and pharmaceutically acceptable salts, esters, amides and prodrugs thereof, wherein X is selected from one of the formulae ##STR2## as well as pharmaceutical compositions containing the same.

Abstract: An electrochemical gas sensor comprises sensing and counter electrodes (1,2). A conduit (15) permits access of gas to the sensing electrode (1). An electrolyte reservoir (23). A porous, block-like body (24) is positioned in the reservoir (23) for conveying electrolyte to the sensing and counter electrodes and at least partly supporting other components of the sensor.

Abstract: Oligopeptide compounds or oligopeptide analogue compounds of the formula A-B-D-E-G-J-L-M-Q are ligands for the anaphylatoxin receptor and are useful in the treatment of inflammatory disease states.Also disclosed are anaphylatoxin receptor ligand compositions and a method for modulating anaphylatoxin activity.

Abstract: Oligopeptide compounds or oligopeptide analogue compounds of the formula A-B-D-E-G-J-L-M-Q are ligands for the anaphylatoxin receptor and are useful in the treatment of inflammatory disease states.Also disclosed are anaphylatoxin receptor ligand compositions and a method for modulating anaphylatoxin activity.

Abstract: A gas diffusion control assembly comprises a gas inlet; a restriction to the rate of flow of gas or vapor from the gas inlet in the form of a porous diffusion barrier extending across the gas inlet; and a polythene disc for causing all gas or vapor passing out of the inlet into the diffusion barrier to diffuse through part of the barrier along a path with a lateral outward component relative to the direction of action through the gas inlet.